India's CRDMO sector is projected to reach US$ 25 billion by 2035, driven by cost advantages, fast project startups, and growing biologics expertise, strengthening its global pharma innovation role.

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical ...

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection by Japan's ...

The Indian Contract Research, Development, and Manufacturing Organization (CRDMO) sector is expected to touch USD 22 billion ...

India's CRDMO sector has the potential to reach USD 22-25 billion by 2035, driven by supply chain de-risking, pricing ...

Hyderabad: The Contract Research, Development, and Manufacturing Organisation (CRDMO) sector in India is at an inflection ...

India is known as the ‘pharmacy of the world,’ dominating generic drug manufacturing. But now, the country is moving up the ...

India's CRDMO sector is poised for significant growth, with potential to reach USD 25 billion by 2035, driven by de-risking ...

India's CRDMO sector, projected to hit $22-25 billion by 2035, is rapidly expanding due to cost advantages and quick startup ...

India currently holds a 2-3 per cent share of the USD 140-145 billion global CRDMO market but has the potential to become a ...

This surge is also being driven by India's cost advantages compared to Western countries, 90 per cent faster project startup ...

The Indian Contract Research, Development, and Manufacturing Organization (CRDMO) sector is at an inflection point, with the potential to grow to $22 - $25 billion by 2035, according to a new report, ...